https://www.selleckchem.com/products/GDC-0449.html
19 test data (1.05%) and UK Biobank participants being more affluent, healthier and less ethnically diverse than the general population. Increasing multimorbidity, especially cardiometabolic multimorbidity, and polypharmacy are associated with a higher risk of developing COVID-19. Those with multimorbidity and additional factors, such as non-white ethnicity, are at heightened risk of COVID-19. Increasing multimorbidity, especially cardiometabolic multimorbidity, and polypharmacy are associated with a higher risk of developing COVID-19.
Like
Comment
Share
